Atlas Rehabilitation And Healthcare At Maywood | |
100 West Magnolia Avenue, Maywood, New Jersey 07607 | |
(201) 843-8411 | |
Name | Atlas Rehabilitation And Healthcare At Maywood |
---|---|
Location | 100 West Magnolia Avenue, Maywood, New Jersey |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 120 |
Occupancy Rate | 93.5% |
Medicare ID (CCN) | 315386 |
Legal Business Name | Maywood Snf Operations Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1821077108 |
Organization Name | YOM TOV CONVALESCENT CENTER, INC. |
Doing Business As | MAYWOOD CENTER FOR HEALTH & REHABILITATION |
Address | 100 W Magnolia Ave, Maywood, NJ 07607 |
Phone Number | 201-843-8411 |
News Archive
An international team of researchers have developed a new substance which uses a two pronged attack on malignant cells.
A new project using artificial intelligence technology could spell a medical breakthrough for people suffering from, or at risk of, coronary artery disease, the single leading cause of death in Australia.
CardioPharma is beginning the final funding phase before submitting an NDA for CardiaPill, the world's first patented triple-combination cardiovascular polypill. "The recent news from Kaiser Permanente reinforces that in this cost containment and efficacy oriented healthcare environment, CardiaPill is in the right place at the right time," stated Don Sellers, CardioPharma's Chairman and CEO.
Revalesio Corporation is pleased to announce a new collaboration with noted neurologist Dr. Roland Martin, Head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich. Dr. Martin will be conducting a Phase IIa clinical trial of RNS60 in patients with relapsing-remitting multiple sclerosis.
› Verified 6 days ago
NPI Number | 1972139178 |
Organization Name | MAYWOOD SNF OPERATIONS LLC |
Address | 100 W Magnolia Ave, Maywood, NJ 07607 |
Phone Number | 201-843-8411 |
News Archive
An international team of researchers have developed a new substance which uses a two pronged attack on malignant cells.
A new project using artificial intelligence technology could spell a medical breakthrough for people suffering from, or at risk of, coronary artery disease, the single leading cause of death in Australia.
CardioPharma is beginning the final funding phase before submitting an NDA for CardiaPill, the world's first patented triple-combination cardiovascular polypill. "The recent news from Kaiser Permanente reinforces that in this cost containment and efficacy oriented healthcare environment, CardiaPill is in the right place at the right time," stated Don Sellers, CardioPharma's Chairman and CEO.
Revalesio Corporation is pleased to announce a new collaboration with noted neurologist Dr. Roland Martin, Head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich. Dr. Martin will be conducting a Phase IIa clinical trial of RNS60 in patients with relapsing-remitting multiple sclerosis.
› Verified 6 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
An international team of researchers have developed a new substance which uses a two pronged attack on malignant cells.
A new project using artificial intelligence technology could spell a medical breakthrough for people suffering from, or at risk of, coronary artery disease, the single leading cause of death in Australia.
CardioPharma is beginning the final funding phase before submitting an NDA for CardiaPill, the world's first patented triple-combination cardiovascular polypill. "The recent news from Kaiser Permanente reinforces that in this cost containment and efficacy oriented healthcare environment, CardiaPill is in the right place at the right time," stated Don Sellers, CardioPharma's Chairman and CEO.
Revalesio Corporation is pleased to announce a new collaboration with noted neurologist Dr. Roland Martin, Head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich. Dr. Martin will be conducting a Phase IIa clinical trial of RNS60 in patients with relapsing-remitting multiple sclerosis.
› Verified 6 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 16.33 | 14.46 |
Percentage of long-stay residents who lose too much weight | 10.65 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 75.53 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.41 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 0.65 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0.32 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 5.54 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 52 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 10.13 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 31.59 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 2.11 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 36.89 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13.68 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 12.03 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 92.52 | 95.98 |
Percentage of short-stay residents who made improvements in function | 68.67 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 55.71 | 82.93 |
News Archive
An international team of researchers have developed a new substance which uses a two pronged attack on malignant cells.
A new project using artificial intelligence technology could spell a medical breakthrough for people suffering from, or at risk of, coronary artery disease, the single leading cause of death in Australia.
CardioPharma is beginning the final funding phase before submitting an NDA for CardiaPill, the world's first patented triple-combination cardiovascular polypill. "The recent news from Kaiser Permanente reinforces that in this cost containment and efficacy oriented healthcare environment, CardiaPill is in the right place at the right time," stated Don Sellers, CardioPharma's Chairman and CEO.
Revalesio Corporation is pleased to announce a new collaboration with noted neurologist Dr. Roland Martin, Head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich. Dr. Martin will be conducting a Phase IIa clinical trial of RNS60 in patients with relapsing-remitting multiple sclerosis.
› Verified 6 days ago
Atlas Rehabilitation And Healthcare At Maywood Location: 100 West Magnolia Avenue, Maywood, New Jersey 07607 Phone: (201) 843-8411 |